Description
Supotaria 100 ml Oral Solution is a medication containing glycopyrronium bromide (1 mg per 5 ml), manufactured by Incepta Pharmaceuticals Ltd. It is primarily indicated for reducing chronic severe drooling (sialorrhea) in pediatric patients aged 3 to 16 years with neurological conditions such as cerebral palsy. Glycopyrronium bromide is an anticholinergic agent that works by inhibiting the action of acetylcholine on salivary glands, thereby decreasing excessive saliva production. The recommended starting dose is 0.02 mg/kg orally three times daily, with gradual titration based on therapeutic response and tolerability, not exceeding 0.1 mg/kg per dose. Administration should be done at least one hour before or two hours after meals, as high-fat food can reduce the oral bioavailability of the solution. Common side effects may include constipation, dry mouth, and urinary retention. Patients should be monitored for these adverse effects, and the medication should be used with caution in individuals with conditions such as glaucoma, gastrointestinal disorders, or renal impairment. Supotaria is not recommended for use in children under 3 years of age. Always consult a healthcare professional before initiating treatment
.jpg)
.jpeg)
.webp)
.jpeg)
.jpg)
.jpg)
.webp)
.png)
.jpg)
 100 IU 3 ML.webp)
.jpg)
.webp)
.jpeg)
.jpg)
.jpeg)
.jpg)
.jpg)
 400MG.jpg)
Change Language